Advertisement
Research Article

Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study

  • Marta Valenciano mail,

    m.valenciano@epiconcept.fr

    Affiliation: EpiConcept, Paris, France

    X
  • Esther Kissling,

    Affiliation: EpiConcept, Paris, France

    X
  • Jean-Marie Cohen,

    Affiliation: Réseau des GROG/Open Rome, Paris, France

    X
  • Beatrix Oroszi,

    Affiliation: National Center for Epidemiology, Budapest, Hungary

    X
  • Anne-Sophie Barret,

    Affiliations: Health Protection Surveillance Centre, Dublin, Ireland, European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden

    X
  • Caterina Rizzo,

    Affiliation: National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Roma, Italy

    X
  • Baltazar Nunes,

    Affiliation: Instituto Nacional de Saúde Dr Ricardo Jorge, Lisbon, Portugal

    X
  • Daniela Pitigoi,

    Affiliations: Cantacuzino Institute, National Institute of Research – Development for Microbiology and Immunology, Bucharest, Romania, Universitatea de Medicina si Farmacie Carol Davila, Bucharest, Romania

    X
  • Amparro Larrauri Cámara,

    Affiliation: National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain

    X
  • Anne Mosnier,

    Affiliation: Réseau des GROG/Open Rome, Paris, France

    X
  • Judith K. Horvath,

    Affiliation: National Center for Epidemiology, Budapest, Hungary

    X
  • Joan O'Donnell,

    Affiliation: Health Protection Surveillance Centre, Dublin, Ireland

    X
  • Antonino Bella,

    Affiliation: National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Roma, Italy

    X
  • Raquel Guiomar,

    Affiliation: Instituto Nacional de Saúde Dr Ricardo Jorge, Lisbon, Portugal

    X
  • Emilia Lupulescu,

    Affiliation: Cantacuzino Institute, National Institute of Research – Development for Microbiology and Immunology, Bucharest, Romania

    X
  • Camelia Savulescu,

    Affiliations: EpiConcept, Paris, France, National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain

    X
  • Bruno C. Ciancio,

    Affiliation: European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

    X
  • Piotr Kramarz,

    Affiliation: European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

    X
  • Alain Moren

    Affiliation: EpiConcept, Paris, France

    X
  • Published: January 11, 2011
  • DOI: 10.1371/journal.pmed.1000388

About the Authors

Marta Valenciano, Esther Kissling, Camelia Savulescu, Alain Moren
EpiConcept, Paris, France
Jean-Marie Cohen, Anne Mosnier
Réseau des GROG/Open Rome, Paris, France
Beatrix Oroszi, Judith K. Horvath
National Center for Epidemiology, Budapest, Hungary
Anne-Sophie Barret, Joan O'Donnell
Health Protection Surveillance Centre, Dublin, Ireland
Anne-Sophie Barret
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden
Caterina Rizzo, Antonino Bella
National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Roma, Italy
Baltazar Nunes, Raquel Guiomar
Instituto Nacional de Saúde Dr Ricardo Jorge, Lisbon, Portugal
Daniela Pitigoi, Emilia Lupulescu
Cantacuzino Institute, National Institute of Research – Development for Microbiology and Immunology, Bucharest, Romania
Daniela Pitigoi
Universitatea de Medicina si Farmacie Carol Davila, Bucharest, Romania
Amparro Larrauri Cámara, Camelia Savulescu
National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
Bruno C. Ciancio, Piotr Kramarz
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Corresponding Author

Email: m.valenciano@epiconcept.fr

Competing Interests

J-M Cohen is a direct advisor for the French Minister of Health (MOH). His salary as Head of réseau des GROG is financed by the French MOH (76%) and Institut Pasteur (24%). The Institut Pasteur contribution is funded by a pool of five pharmaceutical firms (Roche, Glaxo SmithKline [GSK], Sanofi Pasteur, Solvay, Argène). As Head of Open Rome, he is involved in several epidemiological studies that are partially or fully funded by pharmaceutical companies (Sanofi-Pasteur, GSK, Roche), nonprofit organizations (Mutuelles, Résaeu DES France) or public institutions (ECDC, CU Strasbourg). He is a member of Association Mieux Prescrire and the advisory boards of Novartis, Roche, and Wyeth (free participation, no compensation). During the past five years, he has received travel grants from Sanofi-Pasteur and Roche. A. Mosnier is a member of the French MOH advisory board on influenza, and adviser for influenza to the French Health Insurance organization. As coordinator of the Réseau des GROG (French Influenza Sentinel network), her salary is funded by MOH (76%) and Institut Pasteur (24%). Institut Pasteur contribution is funded by a pool of five pharmaceutical firms (GSK, Roche, Sanofi-Pasteur, Solvay, Argène). She is involved, through the other institution with which she is affiliated and salaried (Open Rome research department), in the coordination or analysis of epidemiological studies partially or fully funded by Roche and GSK. She is member of the Groupe d'Expertise et d'Information sur la Grippe (GEIG) Scientific Board. During the last five years, she has received travel grants from Roche for speaking, or participation, at scientific meetings. All other authors have declared that no competing interests exist.

Author Contributions

ICMJE criteria for authorship read and met: M Valenciano, E Kissling, JM Cohen, B Oroszi, AS Barret, C Rizzo, B Nunes, D Pitigoi, AL Cámara, A Mosnier, JK Horvath, J O Donnell, A Bella, R Guiomar, E Lupulescu, C Savulescu, BC Ciancio, P Kramarz, A Moren. Agree with the manuscript s results and conclusions: M Valenciano, E Kissling, JM Cohen, B Oroszi, AS Barret, C Rizzo, B Nunes, D Pitigoi, AL Cámara, A Mosnier, JK Horvath, J O Donnell, A Bella, R Guiomar, E Lupulescu, C Savulescu, BC Ciancio, P Kramarz, A Moren. Designed the experiments/the study: M Valenciano, JM Cohen, C Rizzo, B Nunes, D Pitigoi, AL Cámara, A Mosnier, J O Donnell, R Guiomar, E Lupulescu, C Savulescu, BC Ciancio, P Kramarz, A Moren. Analyzed the data: E Kissling, JM Cohen, AS Barret, C Rizzo, D Pitigoi, A Moren. Collected data/did experiments for the study: JM Cohen, B Oroszi, AS Barret, C Rizzo, B Nunes, D Pitigoi, AL Cámara, A Mosnier, JK Horvath, J O Donnell, A Bella, R Guiomar, E Lupulescu, C Savulescu. Enrolled patients: JM Cohen, C Rizzo, D Pitigoi, A Mosnier, A Bella, E Lupulescu. Wrote the first draft of the paper: M Valenciano. Contributed to the writing of the paper: M Valenciano, E Kissling, JM Cohen, B Oroszi, AS Barret, B Nunes, D Pitigoi, AL Cámara, A Mosnier, JK Horvath, J O Donnell, R Guiomar, E Lupulescu, C Savulescu, BC Ciancio, P Kramarz, A Moren. Coordinated the study at the national level: B Oroszi, C Rizzo, B Nunes, D Pitigoi, A Larrauri Cámara, J O'Donnell. Participated in protocol writing: M Valenciano, A Moren. Contributed to reviewing the data analysis: M Valenciano, A Moren. Wrote first draft and revised the overall manuscript with co-author inputs: M Valenciano. Participated in protocol writing: E Kissling. Adapted GROG network database to I-MOVE design: JM Cohen. Coordinated GROG Network during pandemic phase: JM Cohen. Coordinated the Sentinel network (réseau des GROG) in charge of patient enrollment: A Mosnier. Reviewed drafts of the article: J O'Donnell. Performed the laboratory diagnosis of the influenza virus infection: R Guiomar. Conceived the idea of a European network for monitoring influenza vaccine effectiveness: BC Ciancio.